Puma Biotechnology (PBYI) Work In Process (2020 - 2026)
Puma Biotechnology's (PBYI) quarterly Work In Process came in at $1.9 million in Q1 2026, up 80.36% YoY from $1.1 million in Q1 2025, and up 43.56% on a QoQ basis from $1.3 million in Q4 2025.
Puma Biotechnology (PBYI) Work In Process (2020 - 2026) Analysis & Trends
Puma Biotechnology (PBYI) has 7 years of Work In Process data on file, last reported at $1.9 million in Q1 2026.
- Quarterly Work In Process rose 80.36% year-over-year to $1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 million (up 80.36% YoY) and the FY2025 annual result came in at $1.3 million, up 77.18% from the prior year.
- Work In Process improved to $1.9 million in Q1 2026, from $1.3 million in the prior quarter.
- In the past five years, Work In Process ranged from a high of $7.8 million in Q2 2024 to a low of $758000.0 in Q4 2024.
- A 5-year average of $2.5 million and a median of $2.0 million in 2024 frame the typical range for Work In Process.
- The widest YoY moves for Work In Process: up 169.08% in 2025, down 82.89% in 2025.
- Tracing PBYI's Work In Process over 5 years: stood at $2.7 million in 2022, then plunged by 69.18% to $820000.0 in 2023, then fell by 7.56% to $758000.0 in 2024, then soared by 77.18% to $1.3 million in 2025, then soared by 43.56% to $1.9 million in 2026.
- The last three Work In Process figures came in at $1.9 million (Q1 2026), $1.3 million (Q4 2025), and $5.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Puma Biotechnology | 451.24 Mn | 357.33 Mn | 44.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.79 Mn |
| Mar 31, 2026 | 1.93 Mn |
| Dec 31, 2025 | 1.34 Mn |
| Sep 30, 2025 | 5.40 Mn |
| Jun 30, 2025 | 1.33 Mn |
| Mar 31, 2025 | 1.07 Mn |
| Dec 31, 2024 | 758,000.00 |
| Sep 30, 2024 | 2.01 Mn |
| Jun 30, 2024 | 7.77 Mn |
| Mar 31, 2024 | 2.11 Mn |
| Dec 31, 2023 | 820,000.00 |
| Sep 30, 2023 | 3.43 Mn |
| Jun 30, 2023 | 3.21 Mn |
| Mar 31, 2023 | 1.36 Mn |
| Dec 31, 2022 | 2.66 Mn |
| Sep 30, 2022 | 2.95 Mn |
| Jun 30, 2022 | 3.12 Mn |
| Mar 31, 2022 | 1.61 Mn |
| Dec 31, 2021 | 1.39 Mn |
| Dec 31, 2020 | 1.26 Mn |